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Abstract  
BACKGROUND: The rate of obesity is increasing throughout the world. Obesity in adults’ research 
is characterized by chronic inflammation, associated with type 2 Diabetes and cardiovascular risk. 
The degree to which these changes occur in childhood obesity is not fully defined.  
AIM: This study was designed to explore the relation between circulating levels of pro-inflammatory 
cytokines, and obesity. 
PATIENTS AND METHODS: This cross sectional case control study was carried out in 50 
randomly selected pre-pubertal overweight and obese children compared with fifty apparently 
healthy children of matched age and sex. Serum levels of transforming growth factor-β1, 
interleukin-6, and haptoglobin were quantified by ELISA technique. 
RESULTS: ANOVA test followed by Post Hoc test showed highly significant increase in the serum 
levels of the transforming growth factor-β1, interleukin-6 and haptoglobin among obese children 
compared to overweight and healthy children respectively. The body weight, BMI and BMI z-score 
were significantly positively correlated with serum levels of the three pro-inflammatory cytokines. 
Serum levels of interleukin-6, and haptoglobin were found to be strong predictors of complications 
in severe obesity by linear regression analysis. 
CONCLUSIONS: Obesity is associated with chronic low-grade inflammation. High levels of 
interleukin-6 and haptoglobin are considered to be early biomarkers of inflammation associated with 
severe obesity with subsequent cardiovascular and type 2 diabetes risk. 
 
 
 
 
 
Introduction 
 
Obesity is a serious and progressively 
increasing public health problem that has reached 
epidemic proportions with an increasing worldwide 
prevalence [1]. The prevalence of childhood and 
adolescent obesity has tripled dramatically over the 
last 20–30 years in developed countries, with recent 
estimates to be ~17% in the United States [2]. With 
increasing epidemics of obesity all over the world, 
research in adult populations have established the link 
between elevated inflammatory markers and impaired 
health. Obesity is found to be associated with low-
grade inflammatory process characterized by the 
increase in circulating levels of pro-inflammatory 
cytokines such as transforming growth factor-β1, 
interleukin-6 and acute-phase protein (haptoglobin) in 
healthy obese adults [3-4].  
Haptoglobin is an adiposity and inflammatory 
marker that involved in the liver acute phase response 
to inflammation [5]. The most important functions of 
haptoglobin are to bind free hemoglobin, thus 
preventing its oxidant activity [6]. Interleukin-6 has 
been recently proposed to play a central role in the 
link between obesity, inflammation and coronary heart 
diseases [7-8]. Bastard et al., have suggested that IL-
6 could be involved in insulin resistance and its 
complications [9]. About 15 to 30 % of circulating IL-6 
levels derives from adipose tissue production in the 
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absence of an acute inflammation [10]. It regulates 
energy homeostasis and inflammation; it is capable of 
suppressing lipoprotein lipase activity, and controls 
appetite and energy intake at hypothalamic level [11-
12].  
TGF-β1 is a new multifunctional cytokine that 
is produced by a variety of cells. TGF-β1 activation is 
closely associated with damage the intima media and 
lining endothelium of blood vessels through the 
stimulation of atherosclerotic lesions that is closely 
associated with the development of CVD, including 
hypertension [13], cardiac hypertrophy and cardiac 
fibrosis [14] leading to heart failure, restenosis after 
coronary intervention and thrombosis [15]. In addition, 
inflammatory markers impact metabolic control by 
negatively influencing insulin sensitivity and glucose 
transport. Recent studies have shown a possible 
interaction between TGF-β1 and visceral fat obesity. It 
has been considered to play a central role in the 
development of metabolic syndrome in childhood 
which is predictive of adult metabolic syndrome, non-
alcoholic fatty liver disease and type 2 Diabetes [16]. 
Furthermore, TGF-β1 is a potent initiator of 
proliferation of renal mesangial cells leading to chronic 
kidney disease and there are associations between 
serum level of TGF-β1 and risk factors for progression 
of clinically relevant renal disorders in humans [17].  
Thus, prolonged exposure of obese 
individuals to these inflammatory markers may 
exponentially increase their risk in the development of 
vascular damage, cardiovascular disease, and 
hypertension [18]. In obese children, early 
identification of elevated inflammatory markers and 
development of physical activity interventions are 
important in attenuating the negative health 
consequences that are likely facilitated as they mature 
into adults [19]. The origin of inflammation during 
obesity and the underlying mechanisms that explain 
its occurrence are not still fully understood. To our 
knowledge, no data are available on the physiology, 
predictors and role of haptoglobin, and TGF-β1 in 
childhood obesity. Therefore, the focus of our interest 
was to evaluate predictors of obesity complications 
and the effect of childhood obesity on pro-
inflammatory cytokines production as TGF-β1, IL-6, 
and haptoglobin, and to explore the relation between 
circulating levels of these cytokines and 
anthropometric measures among prepubertal 
overweight and obese Egyptian children. 
 
 
Subjects and Methods 
 
Subjects  
This cross sectional case control study was 
conducted on fifty obese or overweight children 
randomly selected from new cases attending the 
Nutrition Outpatient Clinic of the National Research 
Center for nutritional management during 2014. 
Overweight & obese children were identified using 
BMI for age and sex charts according to standardized 
methods of the World Health Organization (WHO). 
Obesity is defined as BMI and weight for age more 
than 2 SDs above the median value of the WHO 
International Growth References, and BMI z-score 
more than 1.66 SDs above the WHO age and sex 
specific mean for overweight [20]. Inclusion criteria for 
selection included pre-pubertal school overweight & 
obese children with simple obesity. Exclusion criteria 
included children having obesity syndromes, or taking 
medications associated with weight change as 
glucocorticoid therapy. None of the participants had 
chronic illness as cardiovascular or endocrine disease 
as type I or II diabetes, hypothyroidism, and Cushing's 
disease. Age and sex matched fifty apparently healthy 
non obese children have been selected as the control 
group. They recruited from the outpatient' clinic at 
National Research Center. Ethical approval was 
obtained from the Medical Ethical Committee of the 
National Research Center. Written informed consent 
was obtained from the parents after explanation of the 
aim of the study and its possible benefits for 
identifying the cause of the obesity of their children 
and other children who have the same condition. 
 
 
Methods  
 
All children in the study were subjected to full 
personal, past history for systemic diseases, and drug 
administration as corticosteroids. Each child was 
subjected to a complete physical examination and 
anthropometric measures. All measurements were 
made according to techniques described in the 
Anthropometric Standardization Reference Manual 
[20]. Children were weighed (in kg) using a calibrated 
Seca scale to the nearest 0.1 kg (Seca, Hamburg, 
Germany), while height (in cm) was measured using a 
Seca 225 stadiometer to the nearest 0.1 cm with the 
children dressed in minimal clothes, and without 
shoes. Each measurement was taken as the mean of 
three consecutive readings following the 
recommendations of the International Biological 
program [21]. 
For all children, growth parameters including 
BMI (kg/m
2
), and BMI z-scores were computed using 
WHO growth standards [22] with the help of Anthro-
Program of PC, and online software 
(http://www.WHO.gov/epiinfo). Body mass index (BMI) 
was calculated according to the known formula as the 
body weight in kilograms divided by the square of 
height in meters (kg/m
2
) to classify overweight and 
obese children. Assessment of BMI was done using 
categories reported by the world health organization 
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child growth charts standards for age and sex. A body 
mass index below 18.5 means that the child is 
underweight, 18.5 to 24.9 means that the child fall in 
the normal range, 25.0 to 29.9 means child is 
overweight and a score of 30.0 and higher means the 
child is obese.  
Venous blood samples were drawn by 
venipuncture after 12 hours overnight fasting. Blood 
samples were immediately centrifuged, and serum 
was frozen at -80°C until assay. Serum IL-6 was 
determined by Sandwich enzyme linked 
immunosorbent assay (ELISA) as the method using a 
Human IL-6 assay kit provided from Immundiagnostik 
AG, Bensheim, Germany, according to Bauer et al., 
[23]. Quantitative determination of the transforming 
growth factor-β1 (TGF-β1) in serum samples was 
performed by Sandwich enzyme linked 
immunosorbent assay (ELISA) method using Assay 
Max Human transforming growth factor-β1 ELISA Kit 
from Assay Pro Co. , Millipore, St. Charles, MO, 
(USA), according to Kropf et al., [24]. This assay 
employs a quantitative sandwich enzyme 
immunoassay technique that measures TGF-β1 in less 
than 5 hours. Serum haptoglobin was assayed by 
Sandwich enzyme linked immunosorbent assay 
(ELISA) as the method using a Human haptoglobin 
assay kit purchased from Assay Pro Co. (USA) 
according to Van Vlierberghe et al., [25]. This assay 
measures haptoglobin in less than 2 hours.  
 
Statistical analysis 
Statistical analysis was performed using the 
SPSS statistical package software for windows 
version 21 (SSPS Inc, Pennsylvania, and USA). 
Parametric variables are expressed as the mean ± 
SD. Differences between parametric variables among 
the obese and overweight versus control groups were 
evaluated using 2-tailed unpaired t-test. The 
comparison between groups was performed with one 
way analysis of variance (ANOVA) with Post HOC. 
Pearson’s correlation coefficients were used to 
evaluate correlations between the data exhibiting 
parametric distribution. Linear logistic regression 
analysis was performed to examine the relationship 
between serum levels of TGF-β1, interleukin-6, and 
haptoglobin with anthropometric measures. P value 
<0.05 was considered significant difference and 
p<0.001 was considered highly significant difference.  
 
 
Results  
 
A total of fifty overweight and obese children 
aged between 5 to 12 years (mean 9.28 ± 1.96 years) 
were studied. Out of them, 30 children were obese 
and 20 children were overweight. The comparison of 
the anthropometric measures and pro-inflammatory 
cytokines of obese group and overweight group 
versus control group by ANOVA test are shown in 
Table 1. ANOVA test followed by Post Hoc test 
showed statistically highly significant increase in the 
serum levels of TGF-β1, interleukin-6, and haptoglobin 
in obese children compared to overweight children, 
and healthy controls respectively (P<0.001, in all).  
Table 1: The anthropometric measures, and pro-inflammatory 
cytokines of obese group and overweight group versus control group.   
Variables 
Control 
(group III) 
N=50 
Obese group 
(group I) 
N=30 
Overweight 
(group II) 
N=20 
F P-value 
Mean± SD Mean± SD Mean± SD 
Weight (kg)  33.64±6.61 50.8±10.39 46.55±7.23 17.16 <0.001
**
 
Height (cm) 140±12.08 121.07±10.37 128.7±9.7 29.63 <0.001
**
 
BMI (kg/m2) 16.84±1.01 34.81±4.38 27.96±1.71 463.97 <0.001
**
 
BMI z-score 0.12±0.49 2.83±0.44 2.34±0.42 367.33 <0.001
**
 
Serum haptoglobin (g/ml) 2.06±0.76 7.84±1.57 4.69±1.01 253.89 <0.001
**
 
Serum TGF- β1 (ng/ml)  23.76±4.62 45.38±5.14 40.31± 5.22 220.41 <0.001
**
 
Serum IL-6 (pg/mL) 1.13±0.35 12.29± 0.97 8.75±1.55 1549.29 <0.001
**
 
*Significant difference at p<0.05, **highly significant difference at p<0.001.     *** ANOVA. 
 
Serum levels of TGF- β1, IL-6 and haptoglobin 
were significantly positively correlated with the body 
weight, BMI (kg/m
2
) and BMI z-score of 
obese/overweight cases, respectively (P<0.001, in 
all), while serum levels of IL-6 and haptoglobin were 
significantly inversely correlated with their height. 
Serum level of TGF- β1 was significantly positively 
correlated with serum levels of IL-6 and haptoglobin in 
obese and overweight children. Correlations between 
anthropometric measurements and pro-inflammatory 
cytokines in obese/ overweight group are shown in 
Table 2.  
Table 2: Correlations between anthropometric measurements 
and pro-inflammatory cytokines in obese / overweight group. 
 Variables Weight Height BMI 
BMI  
z-score 
Serum 
hapto-
globin 
Serum  
TGF-β1 
Serum 
Haptoglobin 
(g/ml) 
Pearson 
Correlation 
0.435
**
 -0.293
*
 0.876
**
 0.575
**
 1 0.560
**
 
Sig. (2-tailed) 0.002 0.039 .000 0.000  0.000 
Serum TGF- 
β1 (ng/ml) 
Pearson 
Correlation 
0.185
**
 -0.229 0.564
**
 0.391
**
 0.560
**
 1 
Sig. (2-tailed) 0.001 0.109 0.000 0.005 0.000  
Serum IL-6 
(pg/mL) 
Pearson 
Correlation 
0.383
**
 -0.292
*
 0.809
**
 0.512
**
 0.831
**
 0.558
**
 
Sig. (2-tailed) 0.006 0.04 0.000 0.000 0.000 0.000 
*Significant difference at p<0.05, **highly significant difference at p<0.001. 
 
In overweight children, serum level of IL-6 
was significantly positively correlated with BMI (r = 
0.593, P = 0.006), and serum level of haptoglobin (r = 
0.458, P = 0.042), and no significant correlation was 
found between serum levels of IL-6 and TGF-β1 (P > 
0.05). Correlations between serum level of IL-6 and 
BMI, serum levels of haptoglobin and TGF-β1 of 
overweight children are shown in Table 3. 
Table 3: Correlations between serum level of IL-6 and body 
mass index, serum levels of haptoglobin, and TGF- β1 in 
overweight group. 
 
Variable BMI 
Serum 
Haptoglobin 
Serum  
TGF β1 
Serum IL-6 (pg/mL) 
Pearson 
Correlation 
0.593** 0.458* 0.204 
 Sig. (2-tailed) 0.006 0.042 0.389 
*Significant difference at p<0.05, **highly significant difference at p<0.001. 
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To confirm the previous correlations, linear 
regression analysis was done showing the association 
between the different biomarkers studied and body 
mass index. Serum levels of IL-6 and haptoglobin 
were strong predictors in the prediction of obesity 
complications (P < 0.05) as shown in Table 4. 
Table 4:  Linear logistic regression between body mass index 
and serum pro-inflammatory cytokines in obese / overweight 
group. 
 
Variables 
Unstandardized  
coefficients 
Standardized 
coefficients t P-value 
B Std. Error Beta 
Serum haptoglobin (g/ml) 1.500 0.291 0.635 5.154 0.000** 
Serum TGF-β1(ng/ml)  0.065 0.071 0.075 0.912 0.367 
Serum IL-6 (pg/mL) 0.548 0.282 0.239 1.943 0.048* 
Dependent variable: BMI. *Significant difference at p<0.05, **highly significant difference at 
p<0.001. 
 
 
 
Discussion  
 
The National Health and Nutrition 
Examination Survey (NHANES) reported that the 
prevalence of obesity is increasing in all pediatric age 
groups, in both sexes, and in various ethnic and racial 
groups [26]. Higher percentages of obesity among 
Egyptian school children were reported [27- 28].  
Studies in mice and adult humans have 
associated elevated levels of pro-inflammatory 
cytokines with metabolic, cardiovascular diseases 
(CVD) and cardiac death [29-32]. It has not yet been 
shown in prepubertal children how pro-inflammatory 
cytokines and BMI are interrelated. To our best 
knowledge, this current study is considered to be the 
first clinical study that was carried out to evaluate the 
predictors of obesity complications and the effect of 
childhood obesity on pro-inflammatory cytokines 
production as TGF-β1, IL-6, and haptoglobin among 
prepubertal overweight and obese Egyptian children. 
IL-6 is a pro-inflammatory cytokine that plays 
important roles in acute phase reactions, and 
inflammation. It is produced by many cell types, and 
adipose tissue, that enhanced in obesity. It has been 
proposed as a screening tool to assess the risk for 
metabolic syndrome and coronary heart diseases in 
youth [33]. In our present study, serum levels of IL-6 
showed statistically highly significant increase in 
obese children compared to overweight children and 
healthy controls respectively (P<0.001), and its serum 
level was significantly positively correlated with the 
body weight, BMI, and BMI z-score respectively 
(P<0.001). This is in the agreement with Steene et al., 
who reported that, IL-6 correlates with anthropometric 
markers and body composition in childhood. A 
positive association between adipocyte diameter and 
IL-6 levels has been described in humans [34]. It 
means there is a strong relationship between BMI and 
circulating levels of IL-6. 
Haptoglobin levels had been reported to be 
associated with obesity [35], and evaluated for its role 
in inflammation in subjects with increased BMI. The 
increased synthesis of haptoglobin has been thought 
to be a consequence of IL-6, secreted by adipocytes 
[36]. In our present study, serum level of haptoglobin 
showed statistically highly significant increase in 
obese children (F=253.89, P<0.001) compared to 
overweight children and healthy controls respectively, 
and its serum level was significantly positively 
correlated with the body weight, BMI, and BMI z-
score, respectively (P<0.001). It means, there is a 
positive association between BMI and circulating 
levels of haptoglobin. 
TGF-β1 was suggested as an early biomarker 
of inflammation and CVD risk. Although some 
research report increased TGF-β1 level in adipose 
tissue in adults and mice [37], there is limited data in 
the literature concerning TGF-β1 concentration in 
obese humans. In the present study, serum levels of 
TGF-β1 showed statistically highly significant increase 
in obese (F=220.41, P<0.001) compared to 
overweight children and healthy controls respectively. 
This is in the agreement with Romano et al. [38] who 
reported higher serum TGF-β1 levels in obese women. 
On the contrary, other studies in obese adults showed 
decreased levels of TGF-β1 as in a study by Kinik et 
al., [39] who determined that obese children had lower 
TGF-β1 levels compared to leans, however, in a study 
by Kanra et al. [40] who reported the lack that the lack 
of an association between TGF-β1 polymorphisms and 
obesity in Turkish children. 
In light of the current results, serum levels of 
TGF- β1 were found to be significantly positively 
correlated with the body weight, BMI, and BMI z- 
score. Our results is in the agreement with Fain et al., 
[37], who reported that, the TGF-β1 release was 
elevated in the presence of insulin and this may 
explain the positive correlation between BMI and 
TGF-β1 release that they saw in subcutaneous 
adipose tissue and the correlation between total 
release of TGF-β1 and body fat content. Our present 
study is not in the agreement with a study by Yener et 
al., [41] who reported that, serum TGF-β1 levels were 
lower and inversely correlated with body mass index 
(BMI) and waist circumference, and Kinik et al., [39] 
who reported that obese children had lower TGF-β1 
levels compared to leans and the lower TGF-β1 levels 
were not correlated with lipids, insulin resistance and 
BMI. 
IL-6 as a pro-inflammatory cytokine is a main 
stimulator of the production of most acute phase 
protein such as haptoglobin [36], and TGF-β1 [42]. 
This is in favor to our results in which serum level of 
IL-6 is significantly positively correlated with serum 
levels of TGF-β1 and haptoglobin. Moreover, in recent 
years, Aihara  et al., [12], observed that, increasing 
expression of TGF-β1 from fatty tissue affects its 
serum level and hence may stimulate expression of 
the other cytokines. This could be explained why 
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serum level of TGF-β1 was positively correlated with 
serum levels of IL-6 and haptoglobin among obese 
children in our present study. 
Interestingly, linear regression analysis 
revealed that serum levels of IL-6 and haptoglobin 
play a significant role in the pathogenesis of obesity. 
The high serum levels of IL-6 and haptoglobin are 
significant strong predictors of adiposity (p < 0.05 in 
both). It means there is a strong relationship between 
BMI and circulating levels of both IL-6 and 
haptoglobin. This is in the agreement with a study by 
Chiellini et al. [35] who reported that haptoglobin is an 
adiposity marker and its circulating levels being 
significantly related to the degree of obesity. A study 
by Ridker et al., also reported that IL-6 production by 
adipose tissue is enhanced in obesity. One of the 
main effects of IL-6 is the induction of hepatic CRP 
and haptoglobin production, which is known to be an 
independent, major risk marker of metabolic and 
cardiovascular complications [43]. 
In our present study, serum level of IL-6 was 
found to be significantly positively correlated with BMI 
and serum level of haptoglobin and no significant 
correlation was found between serum levels of IL-6, 
and serum level of TGF-β1 in overweight children. We 
found that the increase in the proinflammatory 
cytokines occurs early even in the overweight cases 
and the association between obesity and the 
inflammation markers is dependent on a degree of 
obesity. Our results are in conformity with Skinner et 
al. [44] who reported that, obesity is associated with 
increases in systemic pro-inflammatory markers. The 
association of obesity and low grade inflammation is 
strongly dependent on a degree of obesity. 
In conclusion, our results provided clinical 
evidence that, obesity is associated with a state of 
chronic low-grade inflammation. Obese and 
overweight prepubertal children have elevated serum 
levels of IL-6, and haptoglobin and TGF-β1 which are 
known as markers of inflammation that may increase 
the cardiovascular and/or metabolic disease risk. 
Early identification of pro-inflammatory markers may 
help in identifying those at risk of cardiovascular 
events, and type 2 diabetes mellitus.  
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